|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BRIX1 |
Gene summary for BRIX1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BRIX1 | Gene ID | 55299 |
| Gene name | biogenesis of ribosomes BRX1 | |
| Gene Alias | BRIX | |
| Cytomap | 5p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000027 | UniProtAcc | Q8TDN6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55299 | BRIX1 | LZE2T | Human | Esophagus | ESCC | 1.38e-02 | 6.49e-01 | 0.082 |
| 55299 | BRIX1 | LZE4T | Human | Esophagus | ESCC | 7.48e-10 | 1.71e-01 | 0.0811 |
| 55299 | BRIX1 | LZE7T | Human | Esophagus | ESCC | 3.34e-04 | 6.38e-01 | 0.0667 |
| 55299 | BRIX1 | LZE8T | Human | Esophagus | ESCC | 6.13e-03 | 4.23e-01 | 0.067 |
| 55299 | BRIX1 | LZE20T | Human | Esophagus | ESCC | 2.99e-05 | 6.11e-01 | 0.0662 |
| 55299 | BRIX1 | LZE24T | Human | Esophagus | ESCC | 2.60e-06 | 2.26e-01 | 0.0596 |
| 55299 | BRIX1 | LZE21T | Human | Esophagus | ESCC | 2.14e-03 | -7.30e-03 | 0.0655 |
| 55299 | BRIX1 | LZE6T | Human | Esophagus | ESCC | 4.24e-17 | 1.83e+00 | 0.0845 |
| 55299 | BRIX1 | P1T-E | Human | Esophagus | ESCC | 1.72e-06 | 5.23e-01 | 0.0875 |
| 55299 | BRIX1 | P2T-E | Human | Esophagus | ESCC | 3.67e-25 | 5.28e-01 | 0.1177 |
| 55299 | BRIX1 | P4T-E | Human | Esophagus | ESCC | 1.48e-26 | 1.05e+00 | 0.1323 |
| 55299 | BRIX1 | P5T-E | Human | Esophagus | ESCC | 9.02e-48 | 1.08e+00 | 0.1327 |
| 55299 | BRIX1 | P8T-E | Human | Esophagus | ESCC | 8.50e-21 | 6.33e-01 | 0.0889 |
| 55299 | BRIX1 | P9T-E | Human | Esophagus | ESCC | 3.36e-19 | 5.72e-01 | 0.1131 |
| 55299 | BRIX1 | P10T-E | Human | Esophagus | ESCC | 1.11e-39 | 8.54e-01 | 0.116 |
| 55299 | BRIX1 | P11T-E | Human | Esophagus | ESCC | 4.57e-08 | 5.96e-01 | 0.1426 |
| 55299 | BRIX1 | P12T-E | Human | Esophagus | ESCC | 3.76e-26 | 6.99e-01 | 0.1122 |
| 55299 | BRIX1 | P15T-E | Human | Esophagus | ESCC | 3.67e-15 | 3.51e-01 | 0.1149 |
| 55299 | BRIX1 | P16T-E | Human | Esophagus | ESCC | 1.01e-26 | 6.75e-01 | 0.1153 |
| 55299 | BRIX1 | P17T-E | Human | Esophagus | ESCC | 5.46e-09 | 7.64e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
| GO:0042254111 | Esophagus | ESCC | ribosome biogenesis | 252/8552 | 299/18723 | 3.27e-44 | 1.04e-40 | 252 |
| GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
| GO:0016072110 | Esophagus | ESCC | rRNA metabolic process | 197/8552 | 236/18723 | 1.31e-33 | 1.18e-30 | 197 |
| GO:0006364110 | Esophagus | ESCC | rRNA processing | 189/8552 | 225/18723 | 4.88e-33 | 3.87e-30 | 189 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:0071826111 | Esophagus | ESCC | ribonucleoprotein complex subunit organization | 166/8552 | 227/18723 | 2.94e-17 | 2.42e-15 | 166 |
| GO:0022618111 | Esophagus | ESCC | ribonucleoprotein complex assembly | 159/8552 | 220/18723 | 8.19e-16 | 5.71e-14 | 159 |
| GO:0042273111 | Esophagus | ESCC | ribosomal large subunit biogenesis | 65/8552 | 72/18723 | 1.53e-15 | 9.82e-14 | 65 |
| GO:0042255111 | Esophagus | ESCC | ribosome assembly | 50/8552 | 61/18723 | 5.66e-09 | 1.17e-07 | 50 |
| GO:0000027111 | Esophagus | ESCC | ribosomal large subunit assembly | 22/8552 | 27/18723 | 1.49e-04 | 9.92e-04 | 22 |
| GO:002261312 | Liver | Cirrhotic | ribonucleoprotein complex biogenesis | 231/4634 | 463/18723 | 3.28e-32 | 6.86e-29 | 231 |
| GO:004225412 | Liver | Cirrhotic | ribosome biogenesis | 154/4634 | 299/18723 | 1.18e-23 | 6.72e-21 | 154 |
| GO:000636412 | Liver | Cirrhotic | rRNA processing | 115/4634 | 225/18723 | 1.12e-17 | 1.64e-15 | 115 |
| GO:00160724 | Liver | Cirrhotic | rRNA metabolic process | 119/4634 | 236/18723 | 1.19e-17 | 1.70e-15 | 119 |
| GO:007182612 | Liver | Cirrhotic | ribonucleoprotein complex subunit organization | 115/4634 | 227/18723 | 2.67e-17 | 3.63e-15 | 115 |
| GO:002261812 | Liver | Cirrhotic | ribonucleoprotein complex assembly | 112/4634 | 220/18723 | 4.35e-17 | 5.81e-15 | 112 |
| GO:004227312 | Liver | Cirrhotic | ribosomal large subunit biogenesis | 47/4634 | 72/18723 | 4.20e-13 | 3.29e-11 | 47 |
| GO:00344701 | Liver | Cirrhotic | ncRNA processing | 158/4634 | 395/18723 | 1.09e-11 | 6.96e-10 | 158 |
| GO:004225512 | Liver | Cirrhotic | ribosome assembly | 39/4634 | 61/18723 | 1.07e-10 | 5.72e-09 | 39 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BRIX1 | SNV | Missense_Mutation | c.673N>A | p.Glu225Lys | p.E225K | Q8TDN6 | protein_coding | tolerated(0.07) | possibly_damaging(0.673) | TCGA-A8-A08P-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| BRIX1 | SNV | Missense_Mutation | novel | c.657N>G | p.Asn219Lys | p.N219K | Q8TDN6 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-AC-A6IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| BRIX1 | SNV | Missense_Mutation | c.833N>C | p.Arg278Thr | p.R278T | Q8TDN6 | protein_coding | tolerated(0.52) | benign(0.001) | TCGA-AR-A1AI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD | |
| BRIX1 | SNV | Missense_Mutation | c.1042N>T | p.Asp348Tyr | p.D348Y | Q8TDN6 | protein_coding | deleterious_low_confidence(0.02) | benign(0.009) | TCGA-E2-A15P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
| BRIX1 | SNV | Missense_Mutation | rs374761203 | c.287G>A | p.Arg96His | p.R96H | Q8TDN6 | protein_coding | deleterious(0.03) | benign(0.236) | TCGA-IR-A3L7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| BRIX1 | SNV | Missense_Mutation | rs201632829 | c.490C>T | p.Pro164Ser | p.P164S | Q8TDN6 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD |
| BRIX1 | SNV | Missense_Mutation | novel | c.62N>T | p.Arg21Ile | p.R21I | Q8TDN6 | protein_coding | tolerated(0.08) | benign(0.001) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| BRIX1 | SNV | Missense_Mutation | novel | c.707N>G | p.Phe236Cys | p.F236C | Q8TDN6 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| BRIX1 | SNV | Missense_Mutation | novel | c.234N>A | p.Met78Ile | p.M78I | Q8TDN6 | protein_coding | tolerated(0.13) | possibly_damaging(0.673) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| BRIX1 | SNV | Missense_Mutation | c.953N>C | p.Ile318Thr | p.I318T | Q8TDN6 | protein_coding | deleterious(0) | benign(0.033) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |